Stockscreener 앱 받기
26.05
2.51%
-0.67
시장 영업 전:
27.60
1.55
+5.95%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics eyes FDA approval path for Duchenne cell therapy - MSN
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy - MarketBeat
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (CAPR) Volatility - Stock Traders Daily
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor (NASDAQ: CAPR) reports 2026 shareholder meeting vote tallies - Stock Titan
Capricor Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Capricor Therapeutics to Participate in Upcoming Investor Conferences in Miami - Quiver Quantitative
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Boosts FDA Approval Preparation for Deramiocel - HarianBasis.co
Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy - Insider Monkey
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now - Insider Monkey
Assessing Capricor Therapeutics (CAPR) Valuation After Recent Share Price Cooling And Phase 3 Progress - Sahm
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis - Seeking Alpha
Capricor Shares Fall, FDA Call in August Looms - Bez Kabli
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Capricor expands commercial leadership team - The Pharma Letter
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
How Capricor Therapeutics Inc. (CAPR) Affects Rotational Strategy Timing - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
CAPR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNext Quarter Guidance - thelegaladvocate.com
Capricor Therapeutics (CAPR) names CCO Michael Maurer as SEC reporting insider - Stock Titan
Capricor (CAPR) CCO Michael Maurer awarded 80,000 stock options at $29.36 - Stock Titan
NeoVolta (NEOV) Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock Drops 23.64%Earnings Surprise Report - thelegaladvocate.com
Capricor Therapeutics (CAPR) Slips Slightly as Stock Consolidates Near Key ResistanceFloat Adjusted Cap - thelegaladvocate.com
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut - Sahm
Tesla Launches Full Self-Driving (Supervised) in China Amid Intensifying EV CompetitionRevenue Report - thelegaladvocate.com
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss - Sahm
Capricor Therapeutics says NS Pharma delays could threaten access to Duchenne therapy - MSN
Should you sell your Capricor Therapeutics stock? - Cantech Letter
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks
CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN
1.27%
1.43%
자본화:
|
볼륨(24시간):